Compare NWSA & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWSA | DVA |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | United States |
| Employees | 22300 | N/A |
| Industry | Newspapers/Magazines | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 15.1B |
| IPO Year | N/A | 2003 |
| Metric | NWSA | DVA |
|---|---|---|
| Price | $27.30 | $233.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | $38.18 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 6.7M | 732.3K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.87 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $6.06 | $3.85 |
| Revenue Next Year | $3.25 | $3.07 |
| P/E Ratio | ★ $11.53 | $79.91 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $22.20 | $101.00 |
| 52 Week High | $31.61 | $239.64 |
| Indicator | NWSA | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | 74.75 |
| Support Level | $25.46 | $145.58 |
| Resistance Level | $31.61 | N/A |
| Average True Range (ATR) | 0.81 | 6.30 |
| MACD | 0.24 | 0.51 |
| Stochastic Oscillator | 81.49 | 80.93 |
News Corporation is a diversified media conglomerate with significant presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings platform in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.